Cancer

Cancer refers to a group of more than a hundred diseases that can originate in many different parts of the body. Cancer begins in your cells, which are the building blocks of your body.

Metabolic Flexibility in Cancer: How Diet and Nutrition Shape Tumor Survival and Resistance

Cancer cells survive therapy by dynamically rewiring their metabolism in response to nutrient availability, microenvironmental stress, and therapeutic pressure. This article explains how dietary interventions may exploit metabolic flexibility and plasticity to enhance treatment response while accounting for tumor heterogeneity.

The Effects of Cancer on Family Life

Cancer Prognosis

Hot vs Cold: the differences between tumor types

How Immune Checkpoint Inhibitors have Revolutionized Cancer Treatment

Cancer Screening Considerations: Balancing the Benefits and Risks

TARDIS: The Improved Method of Detecting Breast Cancer

Cancer Pain Management

Nanostructured toxins for the selective destruction of drug-resistant human CXCR4style+ colorectal cancer stem cells

Why are Cancer Cell Lines Useful?

Caring for a Loved One with Cancer

Living with Cancer Pain

See more featured articles »

CDK9 and Cancer

Insights into Oncofertility

Insight into Cancer Vaccines

Cancer History

What Role do Biobanks Play in Cancer Research?

Cancer Plasticity: The Shape-Shifting Threat Challenging Modern Treatments

Microfluidic cancer treatment screen combined with flow cytometry

Acidosis and Tumor Progression

Cancer Pathophysiology

What Causes Cancer?

Cancer Research

Is Cancer a Metabolic Disorder?

Metastatic Migration in Cancer may be Influenced by Metabolism

Cancer Prevention: Lowering your Risk

Exploiting Enzymes in Cancer Diagnosis and Therapy

Assay for Monitoring and Treating Malignant Brain Tumors

Extracellular Vesicles as Floating Cancer Biomarkers

Cancer Pain

How Camomile Could Prevent Neutropenia in Pediatric Leukemia Patients

Using Biomarkers to Detect Cancer

The Biochemistry of Breast Cancer Screening

Cancer Glossary

Cancer Diagnosis

Tyrosine Kinase Inhibitors for Targeted Cancer Therapy

Secondary Lung Cancer

The Cancer Cell Surface Proteome as a Therapeutic Target

Overview of Cell Viability and Cytotoxicity

Effects of Social and Economic Deprivation on Cancer Mortality

Pediatric Cancer

Secondary Brain Cancer

What is the Tumor Microenvironment?

What is Cancer?

British Pioneers in Cancer Biology

Transforming Cancer Care through Genomic Testing

Discovery of Blood Cancer Cells that show Plasma Cell-Like Differentiation

Cancer Classification

Targeted Cancer Therapies

Hypoxia Markers and Their Importance

What is Immunochemotherapy?

Cancer Management

What is Merkel Cell Carcinoma?

Proto-Oncogene Activation: The Genetic Shift that Fuels Cancer

Cancer Symptoms

Investigating the Molecular Mechanisms of Cancer

Cutaneous Manifestations of Internal Malignancy

What is Cancer of Unknown Primary?

Cancer Epidemiology

Myc Mutations and Cancer

What is Tumorigenesis?

Latest Cancer News and Research

Phase two clinical trial demonstrates dramatic mobility gains in children with severe fibrous dysplasia

Fibrous dysplasia is a rare skeletal disorder in which normal bone is gradually replaced by weak fibro-osseous tissue, leading to fractures, pain, deformities, and severe mobility impairment. In many patients, diseased bone tissue produces excessive amounts of fibroblast growth factor-23 (FGF23), a hormone that causes phosphate loss through the kidneys.

21 May 2026

First-of-its-kind pregnancy hormone test reveals why female IBD patients face severe symptom flares

Inflammatory bowel disease (IBD), which comprises the inflammatory conditions Crohn's disease and ulcerative colitis, affects about 1.6 million Americans, many of whom cannot be effectively treated.

21 May 2026

New gene expression signature may guide immunotherapy for resistant prostate cancer patients

Researchers with the James P. Allison Institute™ at The University of Texas MD Anderson Cancer Center have discovered a new gene expression signature within tumors that can help identify patients with metastatic castration-resistant prostate cancer (mCRPC) who are more likely to experience lasting benefits from combined immunotherapy treatment.

21 May 2026

New CA19-9 threshold improves pancreatic cancer risk prediction accuracy

A dual-threshold model for measuring the pancreatic tumor marker serum carbohydrate antigen 19-9 (CA19-9) identified patients with pancreatic cancer who had high-risk disease despite having low CA19-9 levels because of a genetic variation that impairs their ability to produce this biomarker.

21 May 2026

Small T-cell subset drives powerful multiple myeloma immunotherapy responses

Researchers from The University of Osaka find that only a small fraction of T cells may drive the robust anti-cancer response seen in breakthrough multiple myeloma immunotherapy.

21 May 2026

Light-driven nanomotors improve multimodal breast cancer treatment efficacy

The nanomotor starts with bowl‑shaped mesoporous polydopamine (PDA) nanoparticles. These biocompatible bowls are loaded with two key payloads: Fe(II) ions as a Fenton catalyst, and BNN6, a thermally sensitive NO donor.

21 May 2026

Polymer-based immunotherapies enhance tumor targeting and immune activation

Conventional immune checkpoint inhibitors, such as anti-PD-1/PD-L1 and anti-CTLA-4 antibodies, can reinvigorate T cells but typically benefit less than 30% of patients.

21 May 2026

Brain cell division errors may drive cancer and developmental disorders

University of Virginia School of Medicine scientists have revealed how mistakes in the final step of cell division can have dire consequences for developing brain cells.

20 May 2026

Cytokine-armored CAR-T cell therapy successfully attacks aggressive brain tumors in mice

Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have developed a new cytokine-armored CAR-T cell therapy that helps the immune system better attack aggressive brain tumors in mice while reducing dangerous side effects that have long limited immune-based treatments for glioblastoma, one of the deadliest and most treatment-resistant brain cancers.

20 May 2026

Study paves way for earlier pancreatic cancer diagnoses in patients with low-risk pancreatic cysts

Catching pancreatic cancer early can increase the five-year survival rate from 15% to 80%. Patients with pancreatic cysts, frequently detected during unrelated abdominal CT or MRI imaging, can develop malignant pancreatic cancers.

20 May 2026

Restoring ADAR2 enzyme reduces metastatic spread in osteosarcoma

Osteosarcoma is the most common primary bone cancer in children, adolescents, and young adults. Although chemotherapy and surgery have improved survival for localized disease, outcomes remain poor when tumors spread to the lungs or return after treatment.

20 May 2026

New AI framework maps systemic obesity damage at cellular resolution

Researchers at Helmholtz Munich, the Ludwig Maximilians University Munich (LMU) and collaborating institutions have developed an artificial intelligence (AI) framework that maps disease-related changes throughout the entire mouse body at cellular resolution.

20 May 2026

Tumor microenvironment markers forecast immunotherapy response in rare cancers

A new study in Cell Reports Medicine from researchers at The University of Texas MD Anderson Cancer Center identified key features that may help predict which types of rare cancers are likely to respond to immunotherapy.

20 May 2026

Fluid viscosity drives mechanical memory and invasion in glioblastoma

Most cancer studies focus on chemical signals or stiff tumor surroundings, but the stickiness of the fluid itself has received little attention.

20 May 2026

Rerouting dead tumor debris enhances cancer immunotherapy outcomes

As tumors outgrow their blood and nutrient supplies, or respond to treatments like chemotherapy and radiotherapy, individual cancer cells die, exposing their internal scaffolds.

20 May 2026

Engineered nanomaterials optimize delivery barriers in cancer immunotherapy

Cancer immunotherapy works by mobilizing the body's own immune system to recognize and destroy malignant cells.

20 May 2026

Spatial modeling of tissue compartments predicts breast cancer treatment response

HER2-positive breast cancer accounts for about 20% of breast cancer cases and is generally associated with more aggressive behavior and a higher risk of distant metastasis, while pathologic complete response (pCR) after neoadjuvant chemotherapy is strongly linked to better survival outcomes.

20 May 2026